Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IQV | CLUSTER | neutral | 2/10 | CEO Ari Bousbib and CFO Eric Sherbet sold a combined $2.35M in open-market transactions on July 29, 2026, following IQVI | Aug 1, 2026 |
| LLY | COURT-RULING | bearish | 7/10 | The Michigan Supreme Court overruled two long-standing precedents (Smith and Liss) that had broadly exempted regulated i | Aug 1, 2026 |
| GRDX | S-1/A | bearish | 6/10 | GridAI Technologies Corp. filed Amendment No. 2 to its S-1 registration statement to register the resale of 9,908,766 sh | Jul 31, 2026 |
| AVXL | PREC14A | mixed | 7/10 | Anavex Life Sciences is facing a contested proxy fight with activist investor PVG Asset Management, which has nominated | Jul 31, 2026 |
| VRXA | F-1 | bearish | 6/10 | Veraxa Biotech AG filed an F-1 registration statement to register up to 25,000,000 ordinary shares for resale by Lincoln | Jul 31, 2026 |
| NBTX | 6-K | neutral | 1/10 | Nanobiotix filed a routine monthly disclosure of voting rights and share capital as of June 30, 2026, reporting 50,825,6 | Jul 31, 2026 |
| VRXA | F-1 | bearish | 6/10 | Veraxa Biotech AG filed an F-1 registration statement to register the resale of up to 120,295,385 ordinary shares and 6, | Jul 31, 2026 |
| BIAF | 8-K | bearish | 7/10 | bioAffinity Technologies received a Nasdaq staff determination that its common stock bid price closed below $1.00 for 30 | Jul 31, 2026 |
| NWBO | 424B5 | bearish | 6/10 | Northwest Biotherapeutics filed a 424B5 prospectus supplement to register 40,325,000 shares of common stock, primarily r | Jul 31, 2026 |
| AZN | COURT-RULING | neutral | 3/10 | AstraZeneca's challenge to Maine's 340B contract pharmacy law (Chapter 103) was dismissed by the District of Maine. The | Jul 31, 2026 |
| BIVI | S-1/A | bearish | 7/10 | BioVie filed Amendment No. 1 to its S-1 registration statement for a best-efforts offering of up to 56.4 million shares | Jul 31, 2026 |
| SLBT | F-1 | neutral | 4/10 | SL Science Holding Ltd filed an F-1 registration statement to register up to 1,040,000 ordinary shares for resale by PIP | Jul 31, 2026 |
| LLY | COURT-RULING | bullish | 4/10 | The court denied Empower Pharmacy's motion to require Eli Lilly to file a reply addressing state-law regulatory exemptio | Jul 31, 2026 |
| FBLG | PRESS-RELEASE | neutral | 4/10 | FibroBiologics reported Q2 2026 EPS of -$0.66, beating consensus of -$0.93 by 29%, but remains pre-revenue with $3.5M ca | Jul 31, 2026 |
| CDT | 8-K | bearish | 8/10 | CDT Equity Inc. acquired 270 shares of Sarborg Limited (4.76% stake) in exchange for issuing pre-funded warrants to purc | Jul 31, 2026 |
| ARTV | INSIDER-BUY | bullish | 7/10 | RA Capital Management, L.P., a director and 10% owner, purchased $2.05M of ARTV shares in four open-market transactions | Jul 31, 2026 |
| AMGN | 8-K | bearish | 5/10 | Amgen disclosed a material cybersecurity incident involving unauthorized access to cloud environments and exfiltration o | Jul 31, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca's Datroway (datopotamab deruxtecan) received EU approval as monotherapy for 1st-line metastatic triple-negat | Jul 31, 2026 |
| NCEL | 6-K | mixed | 5/10 | NewcelX priced a $1.4M private placement at a 20% premium to market ($4.033/share), selling 347,134 shares and warrants | Jul 31, 2026 |
| TLSA | 6-K | bullish | 5/10 | Tiziana Life Sciences reported quantitative PET imaging results from the third Multiple System Atrophy (MSA) patient in | Jul 31, 2026 |
| GRML | PRESS-RELEASE | neutral | 3/10 | Greenland Mines announced the departure of its support vessel Argus from Reykjavik to the Skaergaard Project, marking th | Jul 31, 2026 |
| OGN | 8-K | bearish | 5/10 | Organon furnished supplemental non-GAAP financial metrics for Q2 2026 via an 8-K, as it has suspended its earnings press | Jul 31, 2026 |
| KPTI | 8-K | mixed | 6/10 | Karyopharm announced Phase 3 XPORT-EC-042 trial failure for selinexor in endometrial cancer (PFS p=0.0791, not significa | Jul 31, 2026 |
| VTGN | 8-K | neutral | 2/10 | Vistagen Therapeutics appointed Douglas J. Williamson, M.D. to its Board of Directors effective July 29, 2026. Dr. Willi | Jul 31, 2026 |
| NVO | 6-K | bearish | 7/10 | Novo Nordisk announced that ziltivekimab failed to reduce MACE vs placebo (HR 0.99, p=ns) in the ZEUS phase 3 CV outcome | Jul 31, 2026 |
| RADX | 6-K | mixed | 6/10 | Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101 (93% primary endpoint concordance) | Jul 31, 2026 |
| VRAX | 6-K | bearish | 7/10 | Virax Biolabs is seeking shareholder approval to increase authorized share capital from 2 million to 500 million ordinar | Jul 31, 2026 |
| MBRX | 8-K | bullish | 6/10 | Moleculin reported updated preliminary blinded results from Part A of its pivotal MIRACLE trial for Annamycin in R/R AML | Jul 31, 2026 |
| ELUT | PRESS-RELEASE | neutral | 1/10 | Elutia Inc. announced it will report its Q2 2026 results on August 13, 2026. | Jul 31, 2026 |
| INO | 8-K | bearish | 6/10 | Inovio Pharmaceuticals priced a $20M public offering of 21M shares and warrants for 42M shares (or pre-funded warrants) | Jul 31, 2026 |